secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2021-09-20T23:59:59+00:00
Accession:  0001453687-21-000113
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Selecta Biosciences appoints Kevin Tan as CFO effective Sept 20, 2021
---------------------------------------------------------------------

- Kevin Tan named CFO; succeeds Ann K. Donohue who steps down as interim CFO but remains VP Finance.
- New CFO will receive $410K base salary, 40% target bonus, $75K signing bonus.
- Granted option to purchase 750K shares vesting over 4 years (25% at 12 months, remainder monthly).
- Tan previously served as Treasurer at Sarepta Therapeutics from July 2020 to September 2021.
- Severance includes 12 months salary, pro-rata bonus, and accelerated equity vesting upon qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/0001453687-21-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/selb-20210920.htm
  HTML page:      https://secwatch.observer/filing/0001453687-21-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer